Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655202 | 1.00 | PARP1 (0.33) | PARP1BTK | |
| SCHEMBL655203 | 0.85 | PARP1 (0.34) | PARP1BTK | |
| SCHEMBL708159 | 0.84 | PIK3CA (0.35) | PARP1 | |
| SCHEMBL708156 | 0.84 | PIK3CA (0.35) | PARP1 | |
| SCHEMBL651186 | 0.79 | MAPT (0.38) | PARP1 | |
| SCHEMBL651184 | 0.79 | MAPT (0.38) | PARP1 | |
| SCHEMBL655204 | 0.77 | ACACB (0.37) | PARP1BTK | |
| SCHEMBL252930 | 0.70 | PARP1 (0.34) | PARP1 | |
| SCHEMBL252931 | 0.70 | PARP1 (0.34) | PARP1 | |
| SCHEMBL252929 | 0.70 | PARP1 (0.34) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | PARP1 4100/4885BTK 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.